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Purpose: Antimicrobial resistance (AMR) is one of the major threats to human health, and 
the high frequency of resistant pathogens in the hospital environment can contribute to the 
transmission of difficult-to-treat health care-associated infections (HAIs). We recently reported 
that, compared with conventional chemical cleaning, the use of a microbial-based sanitation 
strategy (Probiotic Cleaning Hygiene System [PCHS]) was associated with remodulation of 
hospital microbiota and reduction of HAI incidence. Here, we aimed to analyze the impact of 
PCHS on AMR and related effects, such as HAI-associated antimicrobial drug consumption 
and costs.
Patients and methods: Five Italian hospitals, enrolled in a multicenter study where conven-
tional sanitation methods were replaced with PCHS, were included in the analysis. The study 
period included a 6-month observation for each sanitation type. Surface microbiota AMR was 
analyzed using microarray, nested PCR, antibiogram, and microdilution tests. Drug consump-
tion data and related costs were obtained from the medical records of all hospitalized patients 
affected by HAIs.
Results: PCHS use was associated with up to 99% decrease of the AMR genes harbored by 
surface hospital microbiota, independently of the resistance types originally present in each 
individual setting (P
c
<0.01). Functional assays confirmed the molecular data, demonstrating a 
33%–100% decrease of resistant strains depending on the antibiotic type. Antimicrobial drug 
consumption associated with HAI onset showed a global 60.3% decrease, with a 75.4% decrease 
of the associated costs.
Conclusion: The spread of AMR in the hospital environment can be limited by the use of 
sanitation methods to remodulate the hospital microbiota, leading to lower antimicrobial con-
sumption and costs. This approach might be considered as part of broader infection prevention 
and control strategies.
Keywords: AMR, HAI, antimicrobials, drug consumption, costs
Plain language summary
Antimicrobial resistance (AMR) is one of the major threats to human health and is frequently 
found in infections acquired during hospitalization (health care-associated infections [HAIs]). 
AMR can make the pharmacological treatment of infected patients difficult or even impos-
sible. Resistant microbes contaminate the hospital environment, contributing to HAI onset, and 
the chemical sanitation methods typically used for cleaning cannot control AMR, sometimes 
correspondence: elisabetta caselli
section of Microbiology and Medical 
genetics, Department of Medical 
sciences, University of Ferrara, via l. 
Borsari 46, Ferrara 44121, Italy
Tel +39 053 245 5387
Fax +39 053 297 4470
email csb@unife.it
Journal name: Infection and Drug Resistance 
Article Designation: Original Research
Year: 2019
Volume: 12
Running head verso: Caselli et al
Running head recto: Caselli et al
DOI: http://dx.doi.org/10.2147/IDR.S194670
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
8.
11
0.
10
4.
28
 o
n 
27
-M
ar
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Infection and Drug Resistance 2019:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
502
caselli et al
even contributing to the selection of resistant strains. We previ-
ously found that a probiotic-based sanitation method (Probiotic 
Cleaning Hygiene System [PCHS]) stably reduced microbial 
contamination and was associated with a reduction in HAIs in five 
Italian hospitals. In this study, we aimed to analyze the impact of 
PCHS on AMR, as well as the consumption and costs associated 
with HAI-related antimicrobial therapy. The results revealed that 
PCHS use was associated with a decrease of AMR in the surface 
microbiota by up to 99% compared with conventional chemical 
sanitation methods. In addition, a 60.3% decrease in HAI-associated 
antimicrobial consumption was observed, accompanied by a 75.4% 
decrease in the related costs. In conclusion, these findings indicate 
that an environmental intervention effective in altering the hospital 
microbiota can consistently limit the spread of AMR in the hospital 
environment, contributing to containing the incidence of HAIs and 
reducing HAI-related antimicrobial drug consumption and costs, 
and might therefore be considered as a useful component of infec-
tion prevention strategies.
Introduction
The prevention and control of health care-associated infec-
tions (HAIs) depend on multiple factors, including the 
adoption of standard and transmission-based precautions, 
appropriate environmental hygiene, pertinent diagnostics, 
and prudent antibiotic use. HAIs are a global concern, as they 
negatively affect patient outcomes, often increasing both the 
lengths of hospital stay and the associated health care costs. 
In Europe, over 3 million patients acquire HAIs every year, 
with 37,000 deaths occurring as a direct consequence of 
HAIs.1 This is also associated with the increasing antimicro-
bial resistance (AMR) of HAI-associated pathogens,2,3 such 
as vancomycin-resistant enterococci, methicillin-resistant 
staphylococci, and carbapenem-resistant Enterobacteriaceae. 
HAIs tend to exhibit higher resistance rates to antibiotics 
compared with community-acquired infections,4 further 
threatening the outcome of infections in hospitalized patients. 
Consequently, AMR in HAIs is a recognized threat to global 
public health.5
The persistent contamination of hospital surfaces is an 
important contributor to HAI transmission,6–10 as these sur-
faces serve as reservoirs of common pathogens, including 
drug-resistant ones.6,7,9–13 In particular, methicillin-resistant 
Staphylococcus aureus and carbapenem- or even multidrug-
resistant (MDR) Enterobacteriaceae and Pseudomonas 
spp. are frequently detected.6,12,13 Furthermore, we recently 
observed that even less-common types of AMR can be 
detected with substantial frequency in the hospital environ-
ment, such as mcr-1 plasmid-mediated resistance against 
colistin (colR), a last resort drug used to treat infections 
caused by MDR gram-negative bacteria. In fact, up to 8% 
of gram-negative bacteria isolated from the surfaces of Ital-
ian hospitals were found to harbor mcr-1 plasmid-mediated 
colR.14 This value was higher than that found in isolates 
obtained from patients, where plasmid-mediated colR was 
detected in only 1%–2% of isolates, suggesting that the 
hospital environment may be a reservoir for the further 
transmission of colR.14
Conventional sanitation techniques based on the use 
of chemical detergents/disinfectants do not prevent recon-
tamination15,16 and can even potentially contribute to the 
selection of HAI-associated MDR pathogens,17,18 thus 
further worsening the implications of AMR. In contrast, 
we recently reported that a sanitation approach based on 
ecologically sustainable detergents containing spores of 
Bacillus probiotics (PCHS) could decrease the levels of 
surface pathogens by up to 90% more than conventional 
sanitizers,19,20 without inducing the selection of drug-
resistant strains, as demonstrated by molecular analyses 
of the entire microbiota resistome.19,21,22 Furthermore, in a 
recent multicenter study performed in five Italian hospitals 
where PCHS was compared with chemical sanitation, we 
confirmed that PCHS use consistently and stably decreased 
the levels of surface pathogens including resistant ones, and 
this was accompanied by a 52% reduction of HAI incidence 
in hospitalized patients.23
The present study aimed to analyze the AMR character-
istics of the hospital microbiota before and after the intro-
duction of PCHS and evaluate the potential impact of PCHS 
use on HAI-associated antimicrobial drug consumption and 
associated costs.
Patients and methods
study design
The design and type of the multicenter study, which was 
performed over 18 months in five Italian hospitals (ISRCTN 
Registry: ISRCTN58986947), were described previously.23 
Briefly, the Internal Medicine wards of the enrolled hospitals 
were surveyed for 6 months while using the conventional 
chemical-based sanitation method and then for a further 
6 months while using the microbial-based PCHS system. 
PCHS sanitation was performed daily using ecologically 
sustainable detergents containing spores of three Bacillus 
species (Bacillus subtilis, Bacillus pumilus, and Bacillus 
megaterium). The cleaning staff did not change during the 
study period and were trained in the appropriate application 
procedure for PCHS. The training was limited to the correct 
methods for preparing and using the PCHS cleansers, and 
 
In
fe
ct
io
n 
an
d 
Dr
ug
 R
es
ist
an
ce
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
8.
11
0.
10
4.
28
 o
n 
27
-M
ar
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Infection and Drug Resistance 2019:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
503
caselli et al
no other differences were introduced. Hospital personnel and 
inpatients were not aware of the change in the type of sanita-
tion method used. All of the participating hospitals provided 
approval through their local ethics committee and agreed not 
to introduce any other interventions that could potentially 
affect HAI incidence during the study period.
The survey was performed between January 1, 2016, 
and June 30, 2017, and included a 6-month pre-intervention 
period of observation (pre-PCHS), when hospitals maintained 
their conventional chemical-based sanitation procedures, and 
a 6-month post-intervention period of observation (PCHS), 
when PCHS was routinely applied. Both the environmental 
bioburden and HAIs were surveyed throughout the entire 
study period.
analysis of environmental aMR
Specimens of the hospital surface microbiota were collected 
monthly by sampling in duplicate three representative points 
per room (floor, bed footboard, and sink) of three to six ran-
domized rooms per hospital, as previously described.19,21,23 
The total microbial population was collected using sterile 
rayon swabs rubbed on a 10×10 cm area, as previously 
described.21 Total DNA was extracted from the collected 
microbiota samples using the QIAamp UCP Pathogen Mini 
Kit (catalog no. 50214; Qiagen, Hilden, Germany) and 
analyzed using a quantitative PCR microarray detecting 84 
resistance (R) genes (Antibiotic Resistance Genes, catalog 
no. BAID-1901ZRA; Qiagen).21 In total, 756 samples (378 
in the pre-intervention phase and 378 in the intervention 
phase) were analyzed.
All of the surface samples from both the pre-intervention 
and intervention phases of the study were also grown in 
MacConkey broth (catalog no. 402490; Liofilchem, Teramo, 
Italy), which is selective for the Enterobacteriaceae family, 
to amplify the Enterobacteriaceae population and analyze 
the prevalence of the mcr-1 plasmid gene coding for colR. 
The presence of this gene was analyzed using nested PCR 
as previously described.14 The molecular findings were also 
functionally confirmed for individual colonies following 
culture isolation using a broth microdilution assay (SensiT-
est Colistin, catalog no. 75001; Liofilchem), as previously 
described.14 In total, 452 Enterobacteriaceae isolates (223 in 
the pre-intervention phase and 229 in the intervention phase) 
were analyzed.
Furthermore, all of the S. aureus colonies isolated from 
the sampled surfaces were analyzed for drug susceptibility. 
Specifically, the same surface points were sampled using con-
tact (replicate organism direct agar contact) plates containing 
Baird Parker medium (catalog no. 163512; Liofilchem), which 
is selective for Staphylococcus spp. After 48 hours of incuba-
tion at 37°C, presumptive S. aureus colonies were identified 
by biochemical typing (Staph System 18R, catalog no. 71630; 
Liofilchem), isolated, and then characterized for antibiotic 
susceptibility using conventional disk-diffusion Kirby–Bauer 
antibiograms on Mueller–Hinton agar plates (catalog no. 
105437; EMD Millipore, Billerica, MA, USA). The follow-
ing antibiotics were tested: ampicillin (catalog no. CT0003B; 
Oxoid), vancomycin (catalog no. CT0058B; Oxoid), oxacil-
lin (catalog no. CT0040B; Oxoid), cefotaxime (catalog no. 
CT066B; Oxoid), imipenem (catalog no. CT0455B; Oxoid), 
and penicillin G (catalog no. CT0043B; Oxoid). Inhibition 
zone diameters were interpreted according to the European 
Committee on Antimicrobial Susceptibility Testing breakpoint 
tables for the interpretation of minimum inhibitory concentra-
tion (MIC) and inhibition zone diameters24 and the Clinical 
and Laboratory Standards Institute manual (26th edition).25 In 
total, 112 S. aureus isolates (80 in the pre-intervention phase 
and 32 in the intervention phase) were analyzed.
For both S. aureus and Enterobacteriaceae isolates, MDR 
strains were defined as those showing resistance to three or 
more antibiotics, and their incidence was compared for the 
pre-intervention and intervention phases.
analysis of haI-related antimicrobial 
drug consumption
As previously reported,23 all new patients admitted to the 
enrolled wards during the pre-intervention and intervention 
phases were evaluated for the development of HAIs. In total, 
11,461 patients were surveyed, including all HAI types in 
the analysis, which were identified according to the criteria 
defined by the European Center for Disease Prevention and 
Control.26
Antimicrobial consumption data were obtained from 
patients’ medical records. For each patient, two electronic 
clinical records containing general data and information con-
cerning eventual HAI onset, location, etiological agent, drug 
therapy, and infection resolution/outcome were collected. All 
data were anonymized and submitted centrally via a secure, 
password-protected website. Data analyzers were blinded to 
the intervention time and hospital’s group.
analysis of haI-related antimicrobial 
drug costs
Direct costs related to the drug treatment of HAI were evalu-
ated by analyzing the daily cost per patient, including in the 
analysis only the costs of consumed antimicrobial drugs (thus 
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excluding estimates of the costs of health care profession-
als’ time to administer the drugs and the apparatus used, and 
general bed day costs). Each hospital was asked to provide, 
for the different types of antimicrobials used, the cost per 
patient per day of treatment with the standard dose, distin-
guishing also the costs for different routes of administration. 
In case of missing data from a hospital for a particular drug, 
an “average” cost was calculated based on the data provided 
by the other hospitals. The cost of each individual drug treat-
ment per patient was calculated by multiplying the daily 
cost by the treatment duration. The total cost per patient was 
calculated by summing the costs of the different treatments 
administered. The total costs of antimicrobial usage in the 
pre-PCHS and PCHS phases were calculated by summing 
the drug costs for HAI patients in the two groups.
statistical methods
Statistical analyses were performed using the chi-squared 
test and the Mann–Whitney test to evaluate the significance 
of AMR in bacterial isolates and gender differences (male/
female) between the pre-PCHS and PCHS patient groups, 
the Kolmogorov–Smirnov test to evaluate normality, and the 
parametric Student’s t-test to evaluate differences in micro-
array data. P-values of <0.05 were considered to indicate 
statistical significance. Bonferroni correction for multiple 
comparisons was applied for the analysis of microarray data 
(P
c
 values of <0.05 were considered significant). Analyses 
were performed using the IBM SPSS 23 software.
Results
Impact of sanitation method on aMR of 
hospital surface microbiota
Surface bioburden analyses indicated that contamination was 
mostly attributable to the presence of Staphylococcus spp., 
which represented up to 90% of the total surface microbiota, 
although other genera were also present (including Entero-
bacteriaceae spp., Pseudomonas spp., Acinetobacter, Clos-
tridium difficile, and Candida spp.). As reported previously, 
PCHS use was associated with a mean 83% decrease of all of 
the detected pathogens, compared with that detected during 
the pre-intervention phase.23 Detailed analysis of the studied 
pathogen types revealed that PCHS use led to decreases in the 
surface loads of 57.2%–93.3% compared with those detected 
during the pre-PCHS phase, as summarized in Table 1. All 
differences were statistically significant (P<0.05).
Based on these findings, we aimed to examine in detail the 
AMR characteristics of the contaminating population in each 
setting before and after PCHS use. As expected, this analysis 
revealed that the resistance (R) genes harbored by surface 
microbiota in the pre-intervention period exhibited different 
degrees of prevalence in the five enrolled hospitals, potentially 
reflecting the selective pressure exerted in each setting by the 
preferential use of certain antibiotics (Figure 1, left panels). 
Overall, R genes coding for resistance against aminoglycosides, 
fluoroquinolones, macrolides, methicillin, and vancomycin and 
for class-A, class-C, and class-D β-lactamases were detected. 
However, in accordance with the generally high levels of con-
tamination by Staphylococcus spp., the most prevalent R gene 
was mecA, which codes for methicillin resistance and accounted 
for 42.7% of all of the detected R genes in the surface micro-
biota. The genes ermC (26.9%) and msrA (26.6%) were also 
found to be prevalent R genes, whereas all the other identified 
genes represented only 3.8% of the resistome.
Following the introduction of PCHS, significant decreases 
in the R genes present in the microbiota were observed in each 
hospital, compared with those detected in the corresponding 
pre-intervention period (P
c
<0.01), independently of the rela-
tive abundance of specific R genes in the pre-intervention 
phase (Figure 1, right panels). Limiting the analysis exclu-
sively to the most prevalent R genes detected in the surveyed 
settings (ie, those whose amounts were at least one log higher 
than in the negative controls), the introduction of PCHS 
appeared to be associated with a significant 70%–99.99% 
decrease, depending on the type of R gene (Figure 2).
In addition, as staphylococcal contamination was preva-
lent in all of the enrolled hospitals, and due to the impor-
tant role of S. aureus in HAIs, we also examined the drug 
susceptibilities of all the S. aureus strains isolated from the 
hospital surfaces during the study. As such, all the S. aureus 
isolates were analyzed using standard Kirby–Bauer antibio-
grams, as described in the “Patients and methods” section. 
Table 1 Variations in individual pathogens’ load on hospital 
surfaces during pre-Pchs and Pchs (cFU/m2)
Pathogen type Pre-PCHSa PCHSa Decrease (%)
Aspergillus spp. 181±307 12±6 93.3
Candida spp. 2,597±1,798 1,108±559 57.3
Clostridium difficile 334±290 132±219 60.5
Pseudomonas aeruginosa 970±982 415±350 57.2
Acinetobacter baumannii 2,844±841 520±726 81.7
Enterobacteriaceae spp. 1,774±901 189±135 89.3
Staphylococcus spp. 26,947±17,293 4,674±3,799 82.7
Note: aResults are expressed as mean value of cFU/m2 ± SD detected in the five 
enrolled hospitals.
Abbreviations: Pchs, Probiotic cleaning hygiene system; cFU, colony forming 
units.
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Figure 1 Resistome analysis of the hospital surface microbiota. 
Notes: The resistome of the surface contaminant population was analyzed as described in the “Patients and methods” section. The results of the pre-intervention (pre-Pchs, 
left panels) and intervention (Pchs, right panels) phases are shown for each setting (hospitals 1, 2, 3, 4, and 5). The results of the pre-Pchs phase are expressed as the log10 
fold change of each detected R gene compared with the negative controls (nTc), and the results of the Pchs phase are expressed as the log10 fold change of each detected 
R gene compared with the pre-Pchs phase. The plotted data are the mean values obtained in monthly environmental sampling campaigns (12 sampling campaigns) for all of 
the sampled points (18 sampled points per hospital per sampling campaign).
Abbreviation: Pchs, Probiotic cleaning hygiene system.
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The results, which are summarized in Table 2, revealed that, 
compared with those detected in the pre-intervention phase, 
the S. aureus isolates from the post-intervention phase were 
63.9%–93.5% less resistant to antibiotics, depending on the 
antibiotic type. In addition, a global 72.4% decrease of MDR 
S. aureus isolates (defined as those resistant to three or more 
antibiotics), from 58/81 (71.6%) in the pre-PCHS phase to 
16/30 (53.3%) in the PCHS phase, was observed.
We also analyzed the prevalence of mcr-1 plasmid-medi-
ated colR, which was not included in the microarray assay. 
The results revealed that, in contrast to the pre-intervention 
phase, where 21/223 (9.2%) of gram-negative bacteria har-
bored the mcr-1 plasmid, only 6/229 (2.6%) of these isolates 
Figure 2 Resistome analysis of the hospital surface microbiota during the pre-Pchs phase. 
Notes: The resistome of the surface contaminant population was analyzed as described in the “Patients and methods” section. The results of the pre-intervention (pre-
PCHS) phase are plotted according to the prevalence of R genes. The results are the mean values for all five enrolled hospitals obtained in monthly environmental sampling 
campaigns (six sampling campaigns) for all of the sampled points (18 sampled points per hospital per sampling campaign).
Abbreviations: Pchs, Probiotic cleaning hygiene system; cTR, control.
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Table 2 antibiotic resistance in Staphylococcus aureus isolates of pre-Pchs and Pchs phases of the study
Study period Isolates (n) Resistant isolates  
  Penicillin G Ampicillin Vancomycin Oxacillin Cefotaxime Imipenem MDRa
Pre-Pchs 81 53 (65.4%) 58 (71.6%) 31 (38.2%) 50 (61.7%) 61 (75.3%) 42 (51.8%) 58 (71.6%)
Pchs 30 18 (60.0%) 20 (66.6%) 2 (6.6%) 18 (60.0%) 22 (73.3%) 13 (43.3%) 16 (53.3%)
% Decrease 
(strain number)
 –66.0 –65.5 –93.5 –64.0 –63.9 –69.0 –72.4
Notes: aMDR was defined as those strains resistant to three or more antibiotics. Penicillin G (10 IU), ampicillin (10 µg), vancomycin (30 µg), oxacillin (1 µg), cefotaxime 
(30 µg), imipenem (10 µg).
Abbreviation: Pchs, Probiotic cleaning hygiene system.
tested positive for the mcr-1 plasmid R gene in the interven-
tion phase. All of the PCR-positive strains displayed MIC 
values varying from 4 to 16 mg/L in the broth microdilution 
assays and exhibited the MDR phenotype, being resistant to 
three or more antibiotics.
Impact of probiotic-based sanitation 
method on antimicrobial drug 
consumption
Data regarding drug therapy were available for 274/284 
patients who developed an HAI in the pre-PCHS phase (out 
of 5,930 total patients surveyed) and for 124/128 patients 
who developed an HAI in the PCHS phase (out of 5,531 
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total patients surveyed). Table 3 compares the antimicrobials 
administered to these patients in terms of the number of pre-
scriptions and therapy duration (expressed in days). Among 
the antimicrobials used, β-lactams (administered with or 
without β-lactamase inhibitors) and fluoroquinolones were 
the most prevalent, accounting for 58.8% of the total number 
of drugs administered and 55.8% of the total days of therapy. 
Notably, PCHS introduction was associated with a global 
60.3% reduction in drug consumption compared with the 
pre-intervention phase (range 40.5%–90.9%, depending on 
the drug type). In accordance with this, the number of days 
of therapy showed a global 58.6% decrease compared with 
the pre-intervention phase (range 30.8%–97.1%, depending 
on the drug type). The 274 patients from the pre-PCHS phase 
developed 289 episodes of HAI, whereas the 124 patients 
from the PCHS phase developed 128 episodes of HAI; the 
mean number of therapy days for each patient was 12.2 and 
11.1 days (−9%), respectively, in the two phases, whereas 
it was 11.8 and 10.8 (−8.5%) when referring to each HAI 
episode. The detected differences were, however, not statisti-
cally significant.
Impact of probiotic-based sanitation 
method on haI-related antimicrobial 
usage costs
Based on the data obtained for the drug consumption associ-
ated with HAI onset from each enrolled hospital, we evalu-
ated the direct costs related to the antimicrobial treatment of 
HAIs, expressed as the daily cost.
The economic analysis focused on those 398 patients who 
developed at least one HAI during hospitalization and whose 
Table 3 Drug consumption and therapy days during pre-Pchs and Pchs phases of the survey
Drug types Molecules (n) Therapy days (n)
 Pre-PCHS PCHS Pre-PCHS PCHS
β-lactamsa 126 75 (−40.5%) 1,140 711 (−37.6%)
Fluoroquinolones 111 20 (−82%) 723 102 (−85.9%)
glycopeptides 43 18 (−58.1%) 442 178 (−59.7%)
cephalosporins 43 22 (−48.8%) 354 136 (−61.6%)
antifungals 31 6 (−80.6%) 287 41 (−85.7%)
acid antibiotics 11 1 (−90.9%) 68 2 (−97.1%)
Polymixins 7 3 (−57.1%) 85 56 (−34.1%)
sulfamides 6 1 (−83.3%) 43 9 (−79.1%)
aminoglycosides 5 2 (−60.0%) 39 27 (−30.8%)
Others 16 9 (−43.7%) 112 98 (−12.5%)
Total 403 160 (−60.3%) 3,339 1,382 (−58.6%)
Note: aWith or without β-lactamase inhibitors.
Abbreviation: Pchs, Probiotic cleaning hygiene system.
medical records reported complete data on drug therapy, that, 
289 HAI episodes in 274 patients during the pre-intervention 
phase and 128 HAI episodes in 124 patients during the inter-
vention phase. Males accounted for 43.1% and 44.4% of the 
patients in the pre-PCHS and PCHS phases, respectively, and 
the mean age was 76±12.3 years in the pre-PCHS phase and 
78.7±11.3 years in the PCHS phase (Table S1).
Daily costs were available for 281/289 of the HAI episodes 
in the pre-PCHS phase and 127/128 of the HAI episodes in the 
PCHS phase. Data analysis revealed that the mean costs for 
the management of a single HAI episode decreased from € 
213.7±915.3 (Q1, 4.5; median, 17.7; Q3, 63.3) in the pre-PCHS 
period (when conventional chlorine-based sanitizing systems 
were used) to € 116.3±249.9 (Q1, 6.0; median, 25.0; Q3, 64.4) 
in the PCHS phase, representing a 45.6% reduction in the cost 
per HAI episode. The detected differences were, however, 
not statistically significant. Considering the total number of 
patients who experienced HAIs, the overall economic impact 
of HAI-associated drug therapy was € 60,062.17 in the pre-
PCHS phase and € 14,767.16 in the PCHS phase, representing 
a 75.4% reduction in the total antimicrobial costs upon the 
introduction of PCHS, compared with the pre-PCHS phase.
Discussion
AMR is one of the major threats to human health, and the 
persistent contamination of the hospital environment acts as 
a reservoir for the pathogens responsible for HAI onset. The 
control of environmental contamination is a difficult task, and 
the conventional sanitation methods used to date, although 
well intentioned, allow recontamination and can favor the 
selection of resistant strains.
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Our results revealed that PCHS use was associated with 
significant decreases in all the R genes harbored by the surface 
microbiota in the surveyed hospitals, independently of the 
resistance types originally present in each individual setting 
(P
c
<0.01). This reduction was particularly evident for those 
genes that were highly represented in the pre-PCHS phase in 
all the five enrolled hospitals, namely, the genes mecA (coding 
for methicillin resistance), aad1 (aminoglycoside resistance, 
often present in S. aureus), OXA-51 group (β-lactamases, 
oxacillinases), ermA-B-C genes (coding for resistance against 
macrolides, lincosamide, and streptogramin B), and mefA and 
msrA (both coding for macrolide resistance).
These data were confirmed by the results obtained for 
S. aureus isolates through standard antibiogram analysis, 
as PCHS introduction was accompanied by a 61.9%–93.5% 
reduction in resistant isolated strains, depending on the 
antibiotic type, and a total 73.7% decrease in the number of 
strains resistant to three or more antibiotics.
Even less common types of AMR were affected by PCHS 
usage, including the colR provided by the mcr-1 plasmid, 
which decreased by 77.1% in the PCHS phase compared to 
what was detected in the pre-PCHS phase. Although quite 
rare, this type of AMR represents a severe threat to inpa-
tients, as colistin is considered a last resort drug for infec-
tions caused by multi- or pan-drug-resistant gram-negative 
bacteria, thus rendering ineffective any therapeutic option. 
Functional assays, performed by microdilution, confirmed the 
molecular results, demonstrating a concomitant reduction of 
gram-negative MDR strains, as all of the colR isolates also 
exhibited the MDR phenotype.
Overall, these data are consistent with the general 
decrease in surface pathogens previously reported21,23 and 
suggest that PCHS is able to antagonize in a nonspecific 
manner all the pathogens commonly found in the hospital 
environment, thus rendering the detection of drug-resistant 
strains extremely infrequent and unlikely. In accordance with 
this, we previously reported that the number of HAIs was 
significantly diminished (−52.0%).23
Our data demonstrate reductions in both the overall 
impact of HAIs (number of patients with at least one HAI, 
−52%; number of administered drugs, −58.6%; cost, −75.4%; 
and days of therapy, −58.6%) and the severity of individual 
HAI episodes (days of therapy, −8.5% and cost, −45.6%). 
These data show that the overall decreases observed in 
therapy duration and costs both depended on the significant 
drop of HAI incidence during the PCHS phase and suggest 
that they may also have depended on a difference in the treat-
ments necessary for individual HAI episodes.
Limitations 
The present study does, however, have some limitations 
that should be considered. In fact, although the analyses 
were performed on a very large number of patients, which 
likely renders the results representative of clinical reality, 
data analysis was performed by comparing the pre-PCHS 
and PCHS patient groups without any matching of the 
patients themselves. Thus, the clinical characteristics of the 
patients in the two groups may not have been completely 
identical, leading to possible bias in the results. Further-
more, only patients for whom complete data regarding 
drug therapy were available were included, and this may 
have caused underestimation of the total drug consumption 
and costs.
Furthermore, our analysis focused only on drug costs, 
but other parameters should also be included to obtain a 
comprehensive estimate of the management and treatment 
of HAIs, such as the types of apparatus used, the labor costs 
for health care professionals, and the bed day costs. In addi-
tion, the reduction of HAIs may also have an impact on the 
length of hospitalization and related hospitalization costs. 
Taking into account that HAIs and AMR increase the health 
care costs, length of stay in hospitals, morbidity, and mor-
tality, the results of the present study should be considered 
conservative estimates of the possible savings, from a health 
care perspective, that can be obtained using the PCHS system 
in clinical practice.
Conclusion
The findings described in this study indicate that environ-
mental intervention based on microbiota modulation can 
significantly limit the spread of AMR in the hospital envi-
ronment, contributing to containing the risk of infection 
and reducing antimicrobial consumption and the associated 
costs. The results of this study suggest that use of the PCHS 
approach can be considered as part of infection prevention 
and control strategies, and this approach should be further 
explored in future studies both in different settings and for 
its impact on AMR diffusion.
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Supplementary material
Table S1 Demographic characteristics of patients
Patients Pre-PCHS PCHS Differences
No. (%) No. (%) P-value
Total 274 124  
gender (male) 118 (43.1%) 55 (44.4%) n.s.
age (years ± sD) 76.0±12.3 78.7±11.3 0.025
Abbreviations: n.s., nonsignificant; PCHS, Probiotic Cleaning Hygiene System.
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